-
Je něco špatně v tomto záznamu ?
Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside
K. Polaskova, T. Merta, A. Martincekova, D. Zapletalova, M. Kyr, P. Mazanek, Z. Krenova, P. Mudry, M. Jezova, J. Tuma, J. Skotakova, I. Cervinkova, D. Valik, L. Zdrazilova-Dubska, H. Noskova, K. Pal, O. Slaby, P. Fabian, S. Kozakova, J. Neradil,...
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
NV16-34083A
MZ0
CEP - Centrální evidence projektů
NV16-34083A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Plný text - Článek
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
32117783
DOI
10.3389/fonc.2019.01531
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation and histology and all three patients relapsed, but their outcomes differed significantly. The samples of their tumor tissue were analyzed using whole-exome sequencing, gene expression profiling, phosphoproteomic assays, and single-cell phosphoflow cytometry. These results explain different treatment responses of the three histologically identical but molecularly different tumors. Our findings support a personalized approach for patient with high risk, refractory, and rare diseases and may contribute to personalized and customized treatment efforts for patients with limited treatment options like relapsed/refractory Burkitt lymphoma. Summary: The main aim of this study is to analyze three relapsed Burkitt lymphoma patients using a comprehensive molecular profiling, in order to explain their different outcomes and to propose a biomarker-based targeted treatment. In cases 1 and 3, the tumor tissue and the host were analyzed prospectively and appropriate target for the treatment was successfully implemented; however, in case 2, analyses become available only retrospectively and his empirically based rescue treatment did not hit the right target of his disease.
Central European Institute of Technology Masaryk University Brno Czechia
Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005100
- 003
- CZ-PrNML
- 005
- 20210316133852.0
- 007
- ta
- 008
- 200511s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fonc.2019.01531 $2 doi
- 035 __
- $a (PubMed)32117783
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Polaskova, Kristyna $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
- 245 10
- $a Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside / $c K. Polaskova, T. Merta, A. Martincekova, D. Zapletalova, M. Kyr, P. Mazanek, Z. Krenova, P. Mudry, M. Jezova, J. Tuma, J. Skotakova, I. Cervinkova, D. Valik, L. Zdrazilova-Dubska, H. Noskova, K. Pal, O. Slaby, P. Fabian, S. Kozakova, J. Neradil, R. Veselska, V. Kanderova, O. Hrusak, T. Freiberger, GL. Klement, J. Sterba,
- 520 9_
- $a In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation and histology and all three patients relapsed, but their outcomes differed significantly. The samples of their tumor tissue were analyzed using whole-exome sequencing, gene expression profiling, phosphoproteomic assays, and single-cell phosphoflow cytometry. These results explain different treatment responses of the three histologically identical but molecularly different tumors. Our findings support a personalized approach for patient with high risk, refractory, and rare diseases and may contribute to personalized and customized treatment efforts for patients with limited treatment options like relapsed/refractory Burkitt lymphoma. Summary: The main aim of this study is to analyze three relapsed Burkitt lymphoma patients using a comprehensive molecular profiling, in order to explain their different outcomes and to propose a biomarker-based targeted treatment. In cases 1 and 3, the tumor tissue and the host were analyzed prospectively and appropriate target for the treatment was successfully implemented; however, in case 2, analyses become available only retrospectively and his empirically based rescue treatment did not hit the right target of his disease.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Merta, Tomas $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
- 700 1_
- $a Martincekova, Alexandra $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
- 700 1_
- $a Zapletalova, Danica $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
- 700 1_
- $a Kyr, Michal $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
- 700 1_
- $a Mazanek, Pavel $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Krenova, Zdenka $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Mudry, Peter $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Jezova, Marta $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Tuma, Jiri $u Department of Pediatric Surgery, Orthopedics and Traumatology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Skotakova, Jarmila $u Department of Pediatric Radiology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Cervinkova, Ivana $u Department of Pediatric Radiology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Valik, Dalibor $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
- 700 1_
- $a Zdrazilova-Dubska, Lenka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
- 700 1_
- $a Noskova, Hana $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
- 700 1_
- $a Pal, Karol $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
- 700 1_
- $a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
- 700 1_
- $a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czechia.
- 700 1_
- $a Kozakova, Sarka $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
- 700 1_
- $a Neradil, Jakub $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia. Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia.
- 700 1_
- $a Veselska, Renata $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia. Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia.
- 700 1_
- $a Kanderova, Veronika $u Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czechia.
- 700 1_
- $a Hrusak, Ondrej $u Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czechia.
- 700 1_
- $a Freiberger, Tomas $u Central European Institute of Technology, Masaryk University, Brno, Czechia. Faculty of Medicine, Masaryk University, Brno, Czechia. Centre for Cardiovascular Surgery and Transplantation, Brno, Czechia.
- 700 1_
- $a Klement, Giannoula Lakka $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. CSTS Health Care, Toronto, ON, Canada.
- 700 1_
- $a Sterba, Jaroslav $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
- 773 0_
- $w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 9, č. - (2020), s. 1531
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32117783 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20210316133848 $b ABA008
- 999 __
- $a ind $b bmc $g 1524030 $s 1095155
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 9 $c - $d 1531 $e 2019 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
- GRA __
- $a NV16-33209A $a NV16-34083A $p MZ0 $p MZ0
- GRA __
- $a NV16-33209A $a NV16-34083A $p MZ0 $p MZ0
- LZP __
- $a Pubmed-20200511
